Recombinant Human Anti-BCMA x Human Anti-TACI Bispecific Antibody (Diabody-CH3) (BSDBC-H201)

Recombinant Anti-BCMA x Anti-TACI Bispecific Antibody (Diabody-CH3) is a fusion protein of two diabodies connected together by a CH3 region. In a diabody, the two scFvs with short linkers are from anti-BCMA and anti-TACI antibodies. The VH and VL domains form an inter-chain pairing. The diabody with different specificities is fused to each of the CH3 chains, which results in 2+2 antigen-binding valency and extends the half-life of this BsAb. This BsAb can bind two receptors simultaneously. It is designed for the research of Lymphoma therapy.

Datasheet INQUIRY

Specifications

Targets

BCMA & TACI

Type

Constant Domain-extended Bispecific Fragments

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Lymphoma

Targets

Target 1

BCMA

Gene ID

608

UniProt ID

Q02223

Alternative Names

TNFRSF17; tumor necrosis factor receptor superfamily, member 17; BCM; BCMA; CD269; TNFRSF13A; tumor necrosis factor receptor superfamily member 17; B-cell maturation factor; B cell maturation antigen; B-cell maturation protein

Target 2

TACI

Gene ID

23495

UniProt ID

O14836

Alternative Names

TNFRSF13B; tumor necrosis factor receptor superfamily, member 13B; CVID; RYZN; TACI; CD267; CVID2; IGAD2; TNFRSF14B; tumor necrosis factor receptor superfamily member 13B; tumor necrosis factor receptor 13B; transmembrane activator and CAML interactor

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Human Anti-BCMA x Human Anti-TACI Bispecific Antibody (Diabody-CH3) (BSDBC-H201). Click the button below to contact us or submit your feedback about this product.

Recombinant Human Anti-BCMA x Human Anti-TACI Bispecific Antibody (Diabody-CH3) (CAT#: BSDBC-H201)

Specifications

Targets

Customer Reviews and Q&As